{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:05:32Z","timestamp":1789761932677,"version":"4.0.1"},"reference-count":37,"publisher":"Jaypee Brothers Medical Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.59556\/japi.73.0847","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T08:57:10Z","timestamp":1749113830000},"page":"67-72","source":"Crossref","is-referenced-by-count":2,"title":["Biologics and Tuberculosis Preventive Therapy"],"prefix":"10.59556","volume":"73","author":[{"given":"Aloke G","family":"Ghoshal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arup","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20250605085707_B1","article-title":"National Strategic Plan for Tuberculosis: 2017\u201325 Elimination by 2025,","author":"RNTPC.","year":"2017."},{"key":"key20250605085707_B2","article-title":"Guideline for Programmatic Management of Tuberculosis Preventive Treatment in India, National TB Elimination Programme;","year":"2021."},{"issue":"(47):","key":"key20250605085707_B3","doi-asserted-by":"crossref","first-page":"E1314\u2013","DOI":"10.1503\/cmaj.73353","article-title":"No evidence of increased risk of acquired rifampin resistance.","volume":"191","author":"Menzies","year":"2019;","journal-title":"CMAJ"},{"issue":"(5):","key":"key20250605085707_B4","doi-asserted-by":"crossref","first-page":"744\u2013","DOI":"10.3201\/eid1205.050681","article-title":"Isoniazid preventive therapy and risk for resistant tuberculosis.","volume":"12","author":"Balcells","year":"2006;","journal-title":"Emerg Infect Dis"},{"issue":"(8):","key":"key20250605085707_B5","doi-asserted-by":"crossref","first-page":"1065\u2013","DOI":"10.5588\/ijtld.15.0908","article-title":"Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis.","volume":"20","author":"den Boon","year":"2016;","journal-title":"Int J Tuberc Lung Dis"},{"key":"key20250605085707_B6","first-page":"e10.","article-title":"Updates on the risk factors for latent tuberculosis reactivation and their managements.","volume":"5:","author":"Jing-Wen","year":"2016;","journal-title":"Emerg Microbes Infect"},{"issue":"(10228):","key":"key20250605085707_B7","doi-asserted-by":"crossref","first-page":"973\u2013","DOI":"10.1016\/S0140-6736(20)30166-5","article-title":"The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis.","volume":"395","author":"Martinez","year":"2020;","journal-title":"Lancet"},{"key":"key20250605085707_B8","article-title":"Tuberculosis Prevention and Control, Public Health Agency of Canada, Canadian Lung Association\/Canadian Thoracic Society.","volume-title":"Canadian Tuberculosis Standards.","year":"2013.","edition":"7th Edn."},{"issue":"(1):","key":"key20250605085707_B9","doi-asserted-by":"crossref","first-page":"19\u2013","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis.","volume":"55","author":"Jick","year":"2006;","journal-title":"Arthritis Rheum"},{"issue":"(6):","key":"key20250605085707_B10","doi-asserted-by":"crossref","first-page":"1286\u2013","DOI":"10.1378\/chest.13-2137","article-title":"Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. A systematic review and meta-analysis of randomized controlled trials.","volume":"145","author":"Dong","year":"2014;","journal-title":"Chest"},{"key":"key20250605085707_B11","first-page":"28\u2013","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review.","volume":"26:","author":"Ferebee","year":"1970;","journal-title":"Bibl Tuberc"},{"issue":"(7):","key":"key20250605085707_B12","doi-asserted-by":"crossref","first-page":"761\u2013","DOI":"10.3346\/jkms.2012.27.7.761","article-title":"Positive tuberculin skin test or interferon-gamma release assay in patients with radiographic lesion suggesting old healed tuberculosis.","volume":"27","author":"Jeong","year":"2012;","journal-title":"J Korean Med Sci"},{"key":"key20250605085707_B13","first-page":"1136\u2013","article-title":"Radiographic predictors of subsequent reactivation of tuberculosis.","volume":"11:","author":"Linh","year":"2007;","journal-title":"Int J Tuberc Lung Dis"},{"issue":"(8):","key":"key20250605085707_B14","doi-asserted-by":"crossref","first-page":"1018\u2013","DOI":"10.5588\/ijtld.10.0631","article-title":"Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis.","volume":"15","author":"Mandalakas","year":"2011;","journal-title":"Int J Tuberc Lung Dis"},{"issue":"(10):","key":"key20250605085707_B15","doi-asserted-by":"crossref","first-page":"5020\u2013","DOI":"10.4049\/jimmunol.1103556","article-title":"Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ).","volume":"188","author":"Arlehamn","year":"2012;","journal-title":"J Immunol"},{"issue":"(6):","key":"key20250605085707_B16","doi-asserted-by":"crossref","first-page":"e1522\u2013","DOI":"10.1542\/peds.2010-0885","article-title":"Malnutrition and helminth infection affect performance of an interferon gamma-release assay.","volume":"126","author":"Thomas","year":"2010;","journal-title":"Pediatrics"},{"issue":"(RR-6):","key":"key20250605085707_B17","first-page":"1\u2013","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection.","volume":"49","journal-title":"American Thoracic Society."},{"issue":"(1):","key":"key20250605085707_B18","doi-asserted-by":"crossref","first-page":"2\u2013","DOI":"10.4103\/2229-5178.93479","article-title":"Mantoux test and its interpretation.","volume":"3","author":"Nayak","year":"2012;","journal-title":"Indian Dermatol Online J"},{"issue":"(4):","key":"key20250605085707_B19","doi-asserted-by":"crossref","first-page":"428\u2013","DOI":"10.5588\/ijtld.13.0644","article-title":"The \u2019either test positive\u2019 strategy for latent tuberculous infection before anti-tumour necrosis factor treatment.","volume":"18","author":"Jung","year":"2014;","journal-title":"Int J Tuberc Lung Dis"},{"key":"key20250605085707_B20","first-page":"555\u2013","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International union against tuberculosis committee on prophylaxis.","volume":"60:","author":"International Union Against Tuberculosis Committee on Prophylaxis.","year":"1982;","journal-title":"Bull World Health Organ"},{"issue":"(12):","key":"key20250605085707_B21","doi-asserted-by":"crossref","first-page":"e8517.","DOI":"10.1371\/journal.pone.0008517","article-title":"Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review.","volume":"4","author":"van Zyl-Smit","year":"2009;","journal-title":"PLoS One"},{"key":"key20250605085707_B22","first-page":"1\u2013","article-title":"Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An advisory committee statement (ACS).","volume":"34:","author":"Canadian Tuberculosis Committee.","year":"2008;","journal-title":"Can Commun Dis Rep"},{"issue":"(2):","key":"key20250605085707_B23","doi-asserted-by":"crossref","first-page":"283\u2013","DOI":"10.1016\/j.immuni.2008.06.011","article-title":"Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death.","volume":"29","author":"Clay","year":"2008;","journal-title":"Immunity"},{"issue":"(12):","key":"key20250605085707_B24","doi-asserted-by":"crossref","first-page":"2229\u2013","DOI":"10.3899\/jrheum.150057","article-title":"The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-\u03b1 antagonist: a meta analysis of both randomized controlled trials and registry\/cohort studies.","volume":"42","author":"Ai","year":"2015;","journal-title":"J Rheumatol"},{"issue":"(3):","key":"key20250605085707_B25","doi-asserted-by":"crossref","first-page":"522\u2013","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).","volume":"69","author":"Dixon","year":"2010;","journal-title":"Ann Rheum Dis"},{"issue":"(5):","key":"key20250605085707_B26","first-page":"776\u2013","article-title":"Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.","volume":"35","author":"de Leon","year":"2008;","journal-title":"J Rheumatol"},{"issue":"(1):","key":"key20250605085707_B27","doi-asserted-by":"crossref","first-page":"63\u2013","DOI":"10.1378\/chest.11-3157","article-title":"Predictive value of interferon-\u03b3 release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis.","volume":"142","author":"Diel","year":"2012;","journal-title":"Chest"},{"issue":"(31):","key":"key20250605085707_B28","doi-asserted-by":"crossref","first-page":"e11609.","DOI":"10.1097\/MD.0000000000011609","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: pooled efficacy and safety analyses.","volume":"97","author":"Lomonte","year":"2018;","journal-title":"Medicine (Baltimore)"},{"issue":"(7):","key":"key20250605085707_B29","doi-asserted-by":"crossref","first-page":"861\u2013","DOI":"10.1080\/14740338.2020.1774550","article-title":"Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases.","volume":"19","author":"Cantini","year":"2020;","journal-title":"Expert Opin Drug Saf"},{"issue":"(1):","key":"key20250605085707_B30","doi-asserted-by":"crossref","first-page":"141\u2013","DOI":"10.1016\/j.jmii.2017.04.002","article-title":"Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis\u2014a three-year study in Taiwan.","volume":"52","author":"Lin","year":"2019;","journal-title":"J Microbiol Immunol Infect"},{"issue":"(1):","key":"key20250605085707_B31","doi-asserted-by":"crossref","first-page":"15\u2013","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.","volume":"41","author":"Koike","year":"2014;","journal-title":"J Rheumatol"},{"key":"key20250605085707_B32","doi-asserted-by":"crossref","first-page":"56\u2013","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries.","volume":"91:","author":"Cantini","year":"2014;","journal-title":"J Rheumatol Suppl"},{"issue":"(2):","key":"key20250605085707_B33","first-page":"41\u2013","article-title":"Risk of tuberculosis reactivation with rituximab therapy.","volume":"11","author":"Alkadi","year":"2017;","journal-title":"Int J Health Sci (Qassim)"},{"issue":"(3):","key":"key20250605085707_B34","doi-asserted-by":"crossref","first-page":"327\u2013","DOI":"10.2174\/156652407780598557","article-title":"Th2 cytokines in susceptibility to tuberculosis.","volume":"7","author":"Rook","year":"2007;","journal-title":"Curr Mol Med"},{"issue":"(10):","key":"key20250605085707_B35","doi-asserted-by":"crossref","first-page":"800\u2013","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.","volume":"60","author":"British Thoracic Society Standards of Care Committee.","year":"2005;","journal-title":"Thorax"},{"issue":"(4):","key":"key20250605085707_B36","doi-asserted-by":"crossref","first-page":"e0153816.","DOI":"10.1371\/journal.pone.0153816","article-title":"Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: a retrospective nationwide registry of the Korean society of spondyloarthritis research.","volume":"11","author":"Kim","year":"2016;","journal-title":"PLoS One"},{"key":"key20250605085707_B37","unstructured":"Calculator: https:\/\/www.tstin3d.com\/en\/calc.html."}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T08:57:16Z","timestamp":1749113836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-73-3-67"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.59556\/japi.73.0847"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.0847","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}